13 completed, 4 unknown, 2 terminated, 1 not yet recruiting. 20 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 13, Unknown 4, Terminated 2, Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Dyspareunia: new trials by email Literature Review of Dyspareunia trials Research Report on Dyspareunia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial Estradiol 0.01% Vag Cream, testosterone 0.1% and estradiol 0.01% vaginal cream - Vulvodynia, Dyspareunia | Phase 2 / Phase 3 | Not yet recruiting | TriHealth Inc. | 44 | 2025-12-01 | 2025-12-03 |
| Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy Estradiol, Imvexxy, Placebo - Dyspareunia | Phase 3 | Completed | Teva Pharmaceuticals USA | 1050 | 2022-11-15 | 2026-09-30 |
| A Clinical Investigation Into the Effectiveness and Safety of Five Water Based Personal Lubricants. Lubricant A, Lubricant B, Lubricant C - Dyspareunia, Vaginal Dryness | Phase 3 | Completed | Reckitt Benckiser Healthcare (UK) Limited | 183 | 2021-03-01 | 2021-07-02 |
| Clinical Study to Evaluate the Efficacy of Prasterone Treatment for Atrophy Vulvovaginal in Postmenopausal Women With Vulvar / Vestibular Pain Prasterone 6.5 MG, Placebo - Vulvovaginal Atrophy | Phase 3 | Unknown | Dr. Santiago Palacios | 50 | 2020-12-22 | 2021-06-02 |
| Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg) - Endometriosis | Phase 3 | Terminated | Kissei Pharmaceutical Co., Ltd. | 30 | 2020-03-23 | 2025-04-02 |
| Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6) 75 mg linzagolix tablet, 200 mg linzagolix tablet, Placebo tablet to match 75 mg linzagolix tablet - Endometriosis | Phase 3 | Completed | Kissei Pharmaceutical Co., Ltd. | 356 | 2020-03-05 | 2025-04-02 |
| Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream Estradiol 10 MCG Vaginal Tablet [VAGIFEM], Promestriene Vaginal - Vulvovaginal Atrophy | Phase 3 | Completed | Instituto Palacios | 120 | 2020-01-09 | 2021-02-11 |
| Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain. 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg) - Endometriosis | Phase 3 | Completed | Kissei Pharmaceutical Co., Ltd. | 486 | 2019-06-13 | 2025-04-02 |
| A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg) - Endometriosis | Phase 3 | Terminated | Kissei Pharmaceutical Co., Ltd. | 85 | 2019-05-23 | 2025-04-02 |
| Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy Intrarosa, Placebos - Menopause, Genitourinary Syndrome of Menopause | Phase 3 | Unknown | Center for Vulvovaginal Disorders | 40 | 2019-03-02 | 2019-01-31 |
| SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain Relugolix, Estradiol/norethindrone acetate - Endometriosis | Phase 3 | Completed | Myovant Sciences GmbH | 802 | 2018-05-22 | 2023-08-08 |
| The Vaginal Health Trial Vagifem, Replens, Placebo tablet - Atrophy of Vagina, Menopause | Phase 3 | Completed | Fred Hutchinson Cancer Center | 302 | 2016-04-01 | 2018-07-12 |
| Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women Estradiol, Placebo - Vulvovaginal Atrophy, Menopause | Phase 3 | Completed | TherapeuticsMD | 764 | 2014-09-01 | 2017-05-25 |
| Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain Elagolix - Endometriosis | Phase 3 | Completed | AbbVie | 496 | 2014-05-27 | 2021-07-13 |
| Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia WC3011 Estradiol Vaginal Cream, Vehicle - Vulvovaginal Atrophy | Phase 3 | Completed | Warner Chilcott | 550 | 2013-04-12 | 2022-05-09 |
| Therapy to Prevent Sexual Pain in Breast Cancer Survivors Topical liquid lidocaine, Topical saline - Vulvodynia, Dyspareunia | Phase 3 | Completed | OHSU Knight Cancer Institute | 50 | 2011-12-01 | 2017-04-14 |
| Impact of Lactate-Containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors Lactate-containing vaginal lubricant, Placebo vaginal lubricant - Sexual Dysfunction, Breast Cancer Survivors | Phase 3 | Completed | Seoul National University Hospital | 136 | 2009-09-01 | 2017-08-07 |
| Botulinum Toxin Injection for Treatment of Vaginismus botulinum toxin, botulinum toxin A - Vaginismus | Phase 3 | Unknown | Tehran University of Medical Sciences | 40 | 2007-10-01 | 2008-03-18 |
| A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy Synthetic Conjugated estrogens, B, Placebo - Menopause | Phase 3 | Completed | Duramed Research | 300 | 2004-11-01 | 2013-09-02 |
| Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg) Norethindrone Acetate (NA), GnRH Agonist (Lupron Depot) - Endometriosis, Dysmenorrhea | Phase 3 | Unknown | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 112 | 2004-08-01 | 2012-10-25 |
Dysmenorrhea (7) · Endometriosis (7) · Constipation (4) · Breast Neoplasms (2) · Pelvic Pain (2) · Vulvodynia (2) · Pain (1) · Sexual Dysfunction, Physiological (1) · Vaginismus (1) · Vulvar Lichen Sclerosus (1)
Female Urogenital Diseases (20) · Female Urogenital Diseases and Pregnancy Complications (20) · Genital Diseases (20) · Genital Diseases, Female (20) · Genital Diseases, Male (20) · Male Urogenital Diseases (20) · Mental Disorders (20) · Sexual Dysfunctions, Psychological (20) · Urogenital Diseases (20) · Sexual Dysfunction, Physiological (19) · Menstruation Disturbances (7) · Neurologic Manifestations (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7)
Estradiol (5) · linzagolix (4) · Dehydroepiandrosterone (2) · Vaginal Creams, Foams, and Jellies (2) · Botulinum Toxins (1) · Botulinum Toxins, Type A (1) · Control Groups (1) · Gonadotropin-Releasing Hormone (1) · Leuprolide (1) · Norethindrone Acetate (1) · Sodium Chloride (1) · Testosterone (1) · Water (1) · elagolix (1) · estradiol, norethindrone drug combination (1)
Kissei Pharmaceutical Co., Ltd. (4) · AbbVie (1) · Center for Vulvovaginal Disorders (1) · Dr. Santiago Palacios (1) · Duramed Research (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Fred Hutchinson Cancer Center (1) · Instituto Palacios (1) · Myovant Sciences GmbH (1) · OHSU Knight Cancer Institute (1) · Reckitt Benckiser Healthcare (UK) Limited (1) · Seoul National University Hospital (1) · Tehran University of Medical Sciences (1) · Teva Pharmaceuticals USA (1) · TherapeuticsMD (1)
United States (14) · Spain (5) · Canada (4) · Bulgaria (3) · Czechia (3) · Poland (3) · Romania (3) · Ukraine (3) · Austria (2) · France (2) · Hungary (2) · Puerto Rico (2) · Argentina (1) · Australia (1) · Belgium (1)
Andrea Z LaCroix, PhD (1) · Anna Chan, PharmD (1) · C Dias (1) · Caroline Mitchell, MD, MPH (1) · Fernand Labrie, MD (1) · Katherine A Guthrie, PhD (1) · Kirstin Deuble-Bente, Dr. (1) · Martha Goetsch, MD (1) · Myung Jae Jeon, MD (1) · Ozgul Muneyyirci-Delale, M.D. (1)
PMID 18053998, PMID 24807329, PMID 26215946, PMID 28355090, PMID 28383379, PMID 29476499, PMID 29554173, PMID 29738424, PMID 30238814, PMID 30994576, PMID 31688572, PMID 32621325, PMID 32945631, PMID 33367735, PMID 33675793, PMID 33963686, PMID 34054104, PMID 34813408, PMID 34878624, PMID 35353163, PMID 36374501, PMID 37402281, PMID 37619252, PMID 38243752, PMID 38648863, PMID 38906210, PMID 42077502
2017 (1)